Related Experiment Video
Updated: May 14, 2026
09:35
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Beta-cell imaging: call for evidence-based and scientific approach.
Björn A Blomberg1, Ion Codreanu, Gang Cheng
1Department of Radiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Molecular Imaging and Biology
|February 16, 2013
Summary
Positron emission tomography (PET) tracers targeting vesicular monoamine transporter 2 (VMAT2) show promise for imaging pancreatic beta-cell mass (BCM). However, current radiotracers lack specificity and face technical challenges, limiting accurate in vivo BCM quantification.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
- Endocrinology
Background:
- Positron emission tomography (PET) imaging offers potential for developing radiotracers to visualize pancreatic beta-cells.
- Vesicular monoamine transporter 2 (VMAT2) is a target for PET tracers like dihydrotetrabenazine for beta-cell mass (BCM) imaging.
Purpose of the Study:
- To review tetrabenazine-based PET tracers for imaging and quantifying BCM.
- To discuss limitations hindering clinical application of these tracers for in vivo BCM quantification.
Main Methods:
- Overview of tetrabenazine-based PET tracers.
- Discussion of theoretical, technical, and biological limitations.
Main Results:
- Radiotracer specificity for VMAT2 remains a significant hurdle for clinical application.
- Discrepancies exist between radiotracer uptake and actual BCM in various patient groups.
- Technical limitations include PET spatial resolution, partial volume effects, and pancreatic motion.
Conclusions:
- Current tetrabenazine-derived radiotracers cannot accurately quantify BCM per unit volume of pancreatic tissue.
- Technical and biological factors have been overlooked, invalidating claims of precise BCM quantification.
- Further research is needed to overcome limitations for reliable in vivo BCM assessment.
